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Abstract 
Pulmonary arterial hypertension (PAH) is a cardiovascular disorder associated with enhanced 
proliferation and suppressed apoptosis of pulmonary arterial smooth muscle cells (PASMCs). 
Heterozygous mutations in the type II receptor for bone morphogenetic protein (BMPR2) 
underlie the majority of the inherited and familial forms of PAH. The transforming growth 
factor β (TGFβ) pathway is activated in both human and experimental models of PAH. 
However, how these factors exert pro-proliferative and anti-apoptotic responses in PAH 
remains unclear. Using mouse primary PASMCs derived from  knock-in (KI) mice, we 
demonstrated that BMPR-II dysfunction promotes the activation of SMAD-independent 
MAPK pathways via TGF-associated kinase 1 (TAK1), resulting in a pro-proliferative and 
anti-apoptotic response. Inhibition of the TAK1-MAPK axis rescues abnormal proliferation 
and apoptosis in these cells. In both hypoxia and monocrotaline-induced PAH rat models, 
which display reduced levels of bmpr2 transcripts, this study further indicates that the TGFβ-
MAPK axis is activated in lungs following elevation of both expression and phosphorylation 
of TAK1 protein. In ex-vivo cell based assays, TAK1 inhibits BMP-responsive reporter 
activity and interacts with BMPR-II receptor.  In the presence of pathogenic BMPR2 
mutations observed in PAH patients, this interaction is greatly reduced. Taken together, these 
data suggest dysfunctional BMPR-II responsiveness intensifies TGF-TAK1-MAPK 
signaling and thus alters the ratio of apoptosis to proliferation. This axis may be a potential 
therapeutic target in PAH. 
Key words- Pulmonary arterial hypertension, BMPR-II receptor, TGFβ signaling, TAK1 and 
MAPK. 
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Introduction 
Pulmonary arterial hypertension (PAH) is a severe vascular disorder characterized by 
narrowing and obliteration of the small pulmonary arteries due to abnormal proliferation of 
endothelial and smooth muscle cells. Pulmonary vasoconstriction and vascular remodeling 
leads to elevation of pulmonary artery pressure and, in the absence of an effective therapy, 
eventual right-heart failure and death. Heterozygous nonsense mutations in the gene encoding 
the type II receptor for bone morphogenetic protein (BMPR-II), a member of the TGF 
receptor family, underlie the majority of inherited and familial forms of PAH (1). Levels of 
BMPR2 transcripts and proteins are reduced in the lungs in both familial and sporadic PAH 
patients with and without BMPR2 mutation (2, 3). 
 
BMPR-II–mediated signaling regulates vascular cell survival and proliferation, but the 
underlying mechanisms are complicated. BMP2 and 7 inhibit the proliferation of human and 
rat smooth muscle cells (4, 5) via the small mothers against decapentaplegia (SMAD) 
pathway (6). In PASMCs isolated from PAH subjects (PAH-PASMCs), the anti-proliferative 
effect of BMPs (2, 4 and 7) is greatly reduced (7). Furthermore, BMP-promoted apoptosis in 
PAH-PASMCs with reduced BMPR-II protein levels is attenuated (8). Similarly, TGF 
signaling accelerates proliferation in PAH-PASMCs, whereas it inhibits proliferation in 
normal PASMCs (7). Elevated TGF activity has been reported in rat monocrotaline and 
hypoxia models of PAH, and inhibitors of the TGF type I receptor (ALK5) prevent the 
development and progression of disease in these models (9, 10). These findings suggest the 
involvement of an activated TGF pathway in PAH.  
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TGFβ superfamily ligands signal through both SMAD-dependent and SMAD-independent 
pathways. SMAD signaling occurs via either SMAD2/3 (TGFβ) or SMAD1/5/8 (BMP), 
which translocate to the nucleus with the common SMAD (SMAD4)  to directly regulate 
target gene transcription (11). BMPs and TGFβs have both been reported to activate SMAD-
independent mitogen activated protein kinase (MAPK) signaling pathways including ERK, 
JNK and p38MAPK (6). Phosphorylation of p38MAPK and ERK1/2 is increased in PAH-
PASMCs and experimental models of PAH (12-16). Inhibition of MAPK decreases the 
excessive proliferation of PAH-PASMCs (3) and prevents progression of the disease in 
model systems, suggesting that SMAD-independent pathways play a key role in disease 
pathogenesis. However, the molecular mechanism by which TGFβ-induced SMAD-
independent pathways might be activated consequent to impaired BMPR-II signaling remain 
unknown. 
TGF-associated kinase 1 (TAK1), a member of the MAPK kinase kinase (MAPKKK) 
family, has been shown to be an important regulator of SMAD-independent MAPK kinase 
activation in both the TGF and BMP signaling pathways. TAK1 modulates a number of 
processes ranging from innate immune responses to patterning and differentiation via several 
signaling molecules, including p38MAPK, ERK, JNK, NFkappaB and TCFbeta-catenin.  
TAK1 also facilitates cross talk between signaling pathways. Such links via TAK1 have been 
established between TGF and oncogenic R-Ras in the promotion of tumorigenesis (17) and 
between BMP and PI3K/Akt in cardiac cell growth and survival in the postnatal heart (18). 
We hypothesized that the activation of SMAD-independent MAPK pathways in PAH 
consequent to impaired BMPR-II signaling is mediated via TAK1.  
 
In this report, we demonstrated that in mouse PASMCs, BMPR-II dysfunction promotes the 
activation of SMAD-independent MAPK pathways via TAK1 resulting in a pro-proliferative 
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and anti-apoptotic response. Inhibition of the TAK1-MAPK axis rescues abnormal 
proliferation and apoptosis in these cells. We provide in vivo support of the in vitro findings 
in two independent PAH rat models, in which the TGFβ-MAPK axis is activated following 
elevation of both the expression and phosphorylation of TAK1 protein. In ex vivo cell based 
assays, TAK1 interacts with BMPR-II receptor and in the presence of pathogenic BMPR2 
mutation this interaction in greatly reduced. TAK1 attenuates BMP signaling by inhibiting 
the phosphorylation of SMAD1 protein.  
 
Results 
BMPR-II haploinsufficiency potentiates TGFβ signaling, exerting a pro-proliferative 
response in mouse primary PASMCs  
The effect of reduced levels of BMPR-II on TGFβ signaling was investigated in mouse 
primary PASMCs and hypoxia-induced PAH rat lung. The level of plasminogen activator 
inhibitor (PAI-1) transcripts was determined as a measure of TGFβ signaling (9, 10). PAI-1 
expression was increased in transgenic knock-in (KI) mouse primary PASMCs with a PAH-
associated bmpr2 nonsense mutation (bmpr2 
R899X +/-
) compared to wild-type PASMCs 
(bmpr2
+/+
) (Figure 1A).  Reduced levels of transcripts for bmpr2 and the inhibitor of DNA 
binding (Id1), a known BMP target, were seen in mutant cells (see Supplementary Figure 1A-
B).  Increased PAI-1 expression was also observed in hypoxic rat lung tissue compared to 
normoxic control tissue (Figure 1B) with a significant decrease in bmpr2 transcripts 
(Supplementary Figure 1C). Taken together these data suggest a link between dysfunctional 
BMPR-II-mediated signaling and activation of the TGFβ pathway.   
Proliferation was increased in mutant PASMCs compared to wild-type cells (Figure 1C). As 
in human control and PAH-PASMCs (7), TGFβ1 stimulation inhibited proliferation in wild-
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type mouse PASMCs but promoted proliferation in mutant cells (Figure 1D). Inhibition of 
p38MAPK signaling by SB203580 reduced the TGFβ1-stimulated cell proliferation in mutant 
cells.  In these cells, the basal level of p38MAPK phosphorylation is higher, and TGFβ1 
further activates p38MAPK phosphorylation (Figure 1E-F). Taken together, these data 
suggest that the pro-proliferative response of mutant cells to TGFβ1 is mediated via the 
SMAD-independent p38MAPK pathway. 
Small molecule inhibitors of the TGFβ -MAPK axis rescue abnormal cell proliferation 
and apoptosis in mouse PASMCs 
We examined the role of TGFβ-mediated SMAD-independent MAPK axis on pro-
proliferative activity of bmpr2 
R899X +/- 
PASMCs by chemical agents that selectively inhibit 
TGFβ and p38MAPK pathways. For inhibition of TGFβ pathway, we employed SD208 
which is a known inhibitor of ALK5, a TGFβ type I receptor whilst SB203580 was used to 
inhibit p38MAPK pathway. ALK5 and p38MAPK inhibitors inhibited proliferation in mutant 
cells in both the absence (Figure 2A) and presence of TGFβ1 stimulation (Figure 2B), while 
inhibition of p38MAPK had no discernible effect on wild-type cells. We further investigated 
whether TAK1, a known activator of p38MPK pathway is involved in exerting the pro-
proliferative activity in mutant cells. Treatment with the TAK1 inhibitor (5Z)-7- Oxozeaenol 
inhibited proliferation in a dose-dependent manner in mutant but not wild-type cells (Figure 
2C). Oxozeaenol also reduced TGFβ-stimulated mutant cell proliferation in a dose-dependent 
manner (Figure 2D).  
Next, cysteinyl aspartate protease (caspase) activity was used to measure the effect of 
p38MAPK, ALK5 and TAK1 inhibitors on apoptosis in mutant cells. The basal activity level 
of caspases 3 and 7 was attenuated in mutant cells compared to the wild type (Figure 3A), 
and mutant cells showed a greater response to staurosporine (ST), a known inducer of 
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caspase-dependent pathways, than wild-type cells (Figure 3B). Treatment with the ALK5 
inhibitor SD208 was able to promote apoptosis in both wild-type and mutant cells in the 
absence (Figure 3C) and presence of TGFβ1 stimulation (Figure 3D), and inhibition of 
p38MAPK with SB203580 modestly enhanced apoptosis in both wild-type and mutant cells. 
Oxozeaenol promoted apoptosis in a dose-dependent manner and its pro-apoptotic effects 
were higher in mutant PASMCs than in the wild type at the two highest doses used (Figure 
3E). Consistent with our proliferation data, oxozeaenol induced apoptosis in mutant cells in 
the presence of TGFβ stimulation in a dose dependent manner (Figure 3F).  
In addition to activating p38MAPK, the TAK1 pathway has been shown to activate ERK 
phosphorylation, which is increased in PAH-PASMCs (3) and experimental PAH animal 
models (12-16). Similar to the response to oxozeaenol and SB203580 treatment, the ERK 
inhibitor, U0126, activated caspase 3/7 activity in the absence (Supplementary Figure  2A) 
and presence of TGFβ stimulation (Supplementary Figure  2B) in mutant cells.  
Activation of TAK1-MAPK pathways in hypoxia and monocrotaline-induced PAH rat 
lungs 
 Quantitative (Figure 4A) and semi quantitative RT-PCR (Supplementary Figure  3A-B) 
revealed increased TAK1 expression in hypoxic rat lungs compared to normoxic controls.  
Increased TAK1 expression was also observed in PAH-PASMCs harbouring a nonsense 
BMPR2 mutation (p.W9X) compared to normal PASMCs (Supplementary Figure 3C). Four 
isoforms of TAK1 (A-D) have been reported. Western blot analysis of total TAK1 in rat lung 
tissues identified a long and a short isoform and hence designated here as TAK1-LF and 
TAK1-SF, respectively (Supplementary Figure 4A). Phosphorylation of neither the long nor 
the short form was observed in control rat lung tissues (Figure 4B).  Interestingly only the 
TAK1-SF was phosphorylated (Thr184/187) in hypoxic rat lungs after 1 (Figure 4B-C) and 2 
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weeks (Supplementary Figure 4B-C), but not after 2 days. TAK1-SF was also activated 
following monocrotaline treatment at 1 week but not at 2 or 4 weeks (Figure 4D-E and 
Supplementary Figure 4D). The specificity of TAK1-SF was investigated in HEK293 cells. 
In these cells phosphorylated TAK1-SF but not the TAK1-LF was detected which is 
consistent with the manufacturer’s data (Cell Signaling). The specificity of this protein was 
tested using oxozeaenol, SMAD1 overexpression and BMP9 stimulation, all of which 
inhibited phosphorylation, indicating that this protein is TAK1-specific (Supplementary 
Figure 4E). 
The activation of downstream MAPK pathways was investigated in monocrotaline-treated rat 
lungs. Because treatment with the ERK inhibitor, U0126, induced more pro-apoptotic activity 
than the p38MAPK inhibitor, SB203580 (compare Supplementary Figs. 2A and 2B with 
Figs. 3C and 3F, respectively), phosphorylation of ERK1/2 was examined as representative 
of MAPK phosphorylation. Following three weeks of monocrotaline treatment, 
phosphorylation of ERK1/2 in the lungs was elevated (Figure 4F-G), while no significant 
increase was observed after 2 weeks of hypoxic induction (Supplementary Figure 4F). 
Signaling crosstalk between SMAD1 and TAK1-mediated pathways 
We next investigated the effect of canonical BMP-SMAD signaling on TAK1 activity. 
Following BMP9 stimulation, a reduced level of endogenous TAK1-SF phosphorylation was 
observed (Supplementary Figure 5A) in HEK293 cells. In these cells, BMP9 stimulation also 
inhibited transiently overexpressed TAK1. Reduced level of TAK1 phosphorylation was seen 
following SMAD1 overexpression (Supplementary Figure 5B). In the presence of an 
increasing amount of overexpressed TAK1, the SMAD1-mediated inhibition of TAK1 is 
attenuated (Supplementary Figure 5C).  
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The effect of TAK1 on BMP signaling was then investigated using a BMP responsive 3GC-
lux reporter (19). Overexpression of TAK1 inhibited reporter activity in HEK293 cells 
(Figure 5A), and transfection of equimolar concentrations of either BMPR-II or type I 
receptors failed to rescue this TAK1-mediated inhibition (Supplementary Figure 6A). 
Moreover, overexpression of SMAD1 alone enhanced reporter activity, but SMAD1-
mediated reporter activation was markedly reduced in the presence of TAK1 (Supplementary 
Figure 6B). Transfection of increasing amounts of TAK1 demonstrated that the inhibition of 
3GC2-lux reporter activity was dose-dependent (Figure 5B). TAK1-mediated inhibition of 
BMP signaling was independently confirmed by overexpression of an excess amount of 
BMPR-II receptor or SMAD1 relative to TAK1 which rescued reporter activity 
(Supplementary Figure 6C and Figure 5C) and through use of a selective inhibitor of TAK1 
(Oxozeaenol) which promoted BMPR-II–mediated reporter activation in a dose-dependent 
manner (Figure 5D).  
TAK1 interacts with BMPR-II receptor 
Finally, the link between dysfunctional BMPR-II responsiveness and activation of TGFβ-
TAK1-MAPK signaling was investigated. TAK1 interacts with the type II receptor for 
TGFβ1 namely TGFBRII (20). To investigate the efficiency of a potential interaction 
between TAK1 and the BMPR-II receptor, fluorescence and enzyme-based mammalian two-
hybrid assays were performed (Figure 6A). Co-expression of TAK1 and BMPR-II generated 
readily detectable dual fluorescence (Figure 6Biii), suggesting an interaction between BMPR-
II and TAK1. Overexpression of BMPR-II with ALK3, a known BMPR-II interactor (21), 
generated greater dual-fluorescence than cells transfected with BMPR-II and TAK1, 
indicating a weaker interaction between BMPR-II and TAK1 than that observed between 
BMPR-II and ALK3 (Figure 6Biv). Consistent with the results obtained by fluorescence 
microscopy, the determination of fluorescence intensity revealed that the efficiency of the 
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interaction between TAK1 and BMPR-II is weaker than that between BMPR-II and ALK3 
(Supplementary Figure 7A-B). 
To verify these findings, an enzyme-based (luciferase and β-galactosidase) assay was used to 
evaluate the interactions between BMPR-II and TAK1 or ALK3 (Figure 6C). Overexpression 
of BMPR-II with TAK1 generated 200-fold higher luciferase activity compared to reporter 
alone, further confirming an interaction between these two proteins (Figure 6D). In addition, 
we were able to replicate the finding that the interaction between BMPR-II and TAK1 is 
weaker than that of BMPR-II and ALK3 (Figure 6E). Of interest, we noted that the 
interaction between BMPR-II and TAK1 was significantly reduced by introducing known 
pathogenic missense BMPR2 mutations commonly identified in PAH subjects (Figure 6F).  
Discussion 
The present study provides insight into the mechanism by which dysfunctional BMPR-II and 
overactive TGFβ –mediated signaling contributes to both pro-proliferative and anti-apoptotic 
responses leading to the vascular remodelling observed in PAH. In this study we present 
evidence that suggest BMPR-II deficiency activates TGFβ signaling through the SMAD-
independent TAK1-MAPK pathway exerting abnormal proliferation and apoptosis in bmpr2 
R899X
 
+/-
 PASMCs. Inhibition of this TAK1-MAPK axis rescues both abnormal proliferation 
and apoptosis. Furthermore, we provide in vivo support of our in vitro findings that TAK1-
mediated MAPK pathway is activated in both monocrotaline and hypoxia induced PAH rat 
models. We demonstrate that TAK1, a kinase which activates MAPK pathways, binds to the 
BMPR-II receptor. In the presence of PAH-causing BMPR2 mutations this interaction 
between BMPR-II and TAK1 is greatly reduced, which may make TAK1 accessible to TGFβ 
signaling.  
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This study demonstrated several lines of evidence to suggest that the pro-proliferative 
response of TGFβ signaling as a consequence of impaired BMPR-II activity is mediated via 
the TGFβ-TAK1-MAPK axis. We demonstrated that p38MAPK activity and TAK1 
expression are increased in bmpr2-deficient hyperproliferative PASMCs and that the 
excessive proliferation can be selectively reversed by inhibition of both p38MAPK and 
TAK1 supporting the finding that inhibition of p38MAPK reverses the vascular dysfunction 
that is induced by hypoxia (12).  We present evidence that the apoptotic resistant phenotype 
observed in PAH resulting from reduced levels of BMPR-II is modulated via the activation of 
TAK1-dependent MAPK pathways. Apoptosis is attenuated in mutant PASMCs, an effect 
that is mitigated by the inhibition of MAPK pathways including TAK1, p38MAPK and ERK.  
These results imply that BMPR2 deficiency activates TGFβ-TAK1-MAPK signaling, which 
may alter the ratio of cell apoptosis to proliferation and thereby mediating pulmonary 
vascular medial hypertrophy (Figure 7A, 7B). 
Both synergistic and antagonistic influences of TAK1 on SMAD-dependent pathways have 
been reported. TAK1 has been shown to be an essential regulator of BMP signaling and is 
required for the morphogenesis, growth and maintenance of cartilage (22). In contrast, TAK1 
has also been shown to interact with SMAD1-6, which interferes with BMP-induced SMAD 
signaling in murine mesenchymal progenitor cells (23). In addition, TAK1 inhibits TGF-
mediated SMAD activity by promotion of p38MAPK signaling in prostate cancer cells (24). 
In this study, we found that TAK1 inhibits SMAD activity and that the inhibitory effect of 
TAK1 can be overcome by the promotion of SMAD-mediated signaling, which acts to inhibit 
TAK1 phosphorylation, indicating a signaling crosstalk between these two pathways (23). 
These observations support a model in which TAK1 activity is restricted and the protein is 
retained by the SMADs and/or cellular receptors including BMPR-II and TGFBRII. TAK1 
was found to be a BMPR-II–associated protein (18) and, in the presence of pathogenic 
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missense BMPR2 mutations (21), the efficiency of the interaction between TAK1 and 
BMPR-II is markedly reduced. This may impact BMPR-II signaling in two distinct pathways 
(Figure 7A-B). First, an increase in accessible TAK1 may attenuate SMAD signaling to 
below threshold level. Second, the increased availability of TAK1 may activate SMAD-
independent pathways triggered by the overactive TGFβ signaling as well as by the ‘second 
hit’, including inflammation and environmental stress (25) (26).  
In an ex vivo cell-based model, hypoxia has been shown to increase TAK1 activity (27). 
Increased expression and phosphorylation of TAK1 in two independent PAH rat models 
(chronic hypoxia or monocrotaline injection) supports the involvement of activated TAK1-
mediated pathway in PAH.  Elevated levels of phosphorylated ERK1/2, a downstream target 
of TAK1, in monocrotaline-induced PH rat lungs further implies the relevance of the TAK1-
MAPK axis to PAH. As TAK1 is located at the crossroad of several signaling pathways, the 
challenge ahead lies in unraveling the context in which it acts together with cellular 
consequences. 
In summary, we have demonstrated that BMPR2 deficiency exerts pro-proliferative and anti-
apoptotic responses through TGFβ-mediated SMAD-independent pathways and that TAK1 
plays an essential role in fine tuning both SMAD-dependent and -independent effects in 
PAH. TAK1-MAPK signaling is involved in cardiac remodelling following myocardial 
infarction (28) and plays a central role in the maladaptive response to sustained pressure 
overload (29). Given the therapeutic potential of TAK1 inhibition in pancreatic cancer (30) 
and myocardial dysfunction caused by chronic pressure overload (29), we propose that the 
inhibition of the TGF-MAPK axis via TAK1 might provide a novel and effective 
therapeutic intervention in PAH.  
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Materials and Methods 
Further details are provided in Supplementary Materials and Methods. 
RNA isolation, cDNA synthesis and reverse Transcriptase PCR (RT-PCR) 
Complementary DNA (cDNA) was synthesized using random primers (Roche) and MMLV 
Reverse Transcriptase (Promega) using RNAs isolated from lung samples as described (31). 
PCR was carried out using Hi-Fidelity Extensor Master Mix (ABgene).  
Cell culture, transient transfection, enzymatic assay and western blots 
Cell culture and transfections were carried out as described elsewhere (21) (32). Luciferase 
and β-galactosidase activities were determined with the Dual-light Reporter Assay (Applied 
Biosystems) using an ORION-II Plate Luminometer (Berthold) according to manufacturer’s 
protocols. BMP-responsive reporter assay in mammalian cells was performed as previously 
described (21). Western blots were carried out using anti-phospho specific p38MAPK 
(Thr180/Thr182), TAK1 (Thr184/187), ERK1/2 (Thr202/Tyr204) and total TAK1 (Cell 
Signaling) antibodies following manufacturer’s protocols. To confirm equal loading the 
membranes were stripped and re-probed with anti-β-actin antibody (Cell Signaling).  
Determination of protein-protein interactions, quantification of proliferation and 
apoptosis of mouse primary PASMCs 
Efficiency of protein-protein interactions between TAK1 and BMPR-II in mammalian cells 
was determined as previously reported (33). Relative rate of proliferation and apoptosis of 
mouse PASMC was carried out using CellTiter 96
®
 Aqueous One Solution Cell Proliferation 
Assay and Caspase-Glo
®
 3/7 Assay (Promega) following manufacturer’s instruction. 
The hypoxia and monocrotaline induced PAH rat models 
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Two experimental PAH models induced by chronic hypoxia and monocrotaline (MCT) were 
employed. Chronic hypoxia rats were exposed to 10% O2 in the normorbaric chamber and 
MCT rats were injected subcutaneously in a hind limb with MCT (60 mg/kg, Sigma). The 
lungs were collected from control, 2 days, 1 week, 2 weeks hypoxia rats (n=3-4) and 1 week, 
2 weeks, 3 weeks and 4 weeks after MCT (n=3-4) injection and stored at -80ºC.  
Statistics 
The data were expressed as mean + SD and analyzed using the student’s T-test. One way 
analysis of variance (ANOVA) followed by Turkey’s post hoc tests were carried out for 
comparison of multiple means.  A p-value of < 0.05 indicated statistical significance. 
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 Figure Legends 
Figure 1 
Dysregulated BMPR-II signaling exerts pro-proliferative activity through the activation of 
TGFβ signaling. (A) PAI-1 expression in mouse primary PASMCs derived from wild-type 
(bmpr2
+/+
) and mutant (bmpr2 
R899X+/-
) mice and (B) hypoxic rat lung. (C) The effect of 
TGFβ1 induced p38-MAPK signaling on PASMC proliferation. The relative proliferation 
rate of wild-type cells was set as 100.  (D) Anti- and pro-proliferative responses to TGFβ1 in 
wild-type and mutant cells. The proliferation rate of both unstimulated wild-type and mutant 
cells was set as 100. (E) Phosphorylation (Thr180/Thr182) of p38MAPK in PASMCs. 
TGFβ1 stimulation is indicated by (+). (F) Quantification of p38MAPK phosphorylation 
derived from three independent western blot analyses.  *P<0.05, **P<0.01 and ***P<0.001 
compared with normoxic, wild-type or cells stimulated with TGFβ1. 
Figure 2 
Inhibition of abnormal cell proliferation by selective small molecule inhibitors of TAK1-
MAPK pathways in mouse primary PASMCs. (A) The relative level of proliferation of 
mutant PASMCs compared to wild-type in the presence of 10µM of SD208 and SB203580. 
(B) As in (A), following stimulation with TGF1. (C) The dose-dependent effect of 
oxozeaenol on the proliferation of wild-type and mutant PASMCs. (D) The inhibitory effect 
of SB203580 and oxozeaenol on mutant PASMCs. The concentration of TGFβ was 10 ng/ml 
and the concentration of the inhibitors used was as indicated. Black and grey bars represent 
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wild-type and mutant cells, respectively. The relative proliferation rate of both wild-type and 
mutant cells was set at 100.  Data are presented as the mean ± SD from 3–6 independent 
experiments. *P<0.05, **P<0.01 and ***P<0.001 compared with wild-type, mutant or cells 
stimulated with TGFβ1. 
Figure 3 
Activation of apoptosis by small molecule drugs that target the TAK1-MAPK pathways. 
Relative caspase 3/7 activity of (A) wild-type and mutant PASMCs (B) in the presence and 
absence of staurosporine (ST) or (C) in the presence of SD208 and SB203580. (D) As in (C), 
following stimulation with TGF1. (E) The effect of oxozeaenol on caspase activity in wild-
type and mutant PASMCs. (F) The effect of SB203580 and oxozeaenol on caspase 3/7 
activity in mutant PASMCs following TGFβ1 stimulation. The relative caspase activity of 
untreated cells was set at 100. Data are presented as the mean ± SD from 3 independent 
experiments. The relative caspase activity of both wild-type and mutant cells was set at 100. 
*P<0.05, **P<0.01 and ***P<0.001 compared with wild-type, mutant or cells stimulated 
with TGFβ1. 
Figure 4 
Activation of the TAK1 pathway in hypoxic and monocrotaline-induced PAH rat lung tissue. 
(A) The relative level of TAK1 transcript in normoxic control and hypoxic rat lung. (B) 
Western blot using phospho-TAK1 (Thr184/187) antibody in a time course of hypoxic rat 
lungs and (C) quantification of phospho-TAK1 western blots relative to β-actin. (D) 
Phosphorylation of TAK1 following 1 week of monocrotaline treatment (MCT) and (E) 
quantification of phospho-TAK1 western blot images. (F-G) Elevated levels of ERK1/2 
phosphorylation in rat lungs following 3 weeks of monocrotaline treatment as demonstrated 
by immunoblotting. *P<0.05 and **P<0.01 compared with control. 
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Figure 5 
Inhibition of BMP signaling by TAK1. (A) The effect of TAK1 on BMP signaling measured 
with the 3GC2-Lux reporter (19) in the presence of plasmids encoding BMPR-II, ALK3, 
ALK6, and TAK1. (B) The efficiency of TAK1-mediated inhibition of the reporter. (C) 
Competition between TAK1 and SMAD1. Concentration of the TAK1 plasmid was 0.25 ng 
while the SMAD1 plasmid was transfected at 1:1, 1:10, 1:100 and 1:1000, as indicated. The 
presence and absence of the TAK1 and SMAD1 plasmids are indicated by (+) and (-), 
respectively. (D) The effect of oxozeaenol treatment on TAK1-mediated inhibition of 
reporter activity. Data are presented as the mean ± SD from 3–6 independent experiments. 
*P<0.05, **P<0.01 and ***P<0.001 compared to the reporter. 
Figure 6 
Interaction of TAK1 and BMPR-II determined by  mammalian two hybrid protein-protein 
interaction assay (33). (A) Dual-light reporter assay. In the event of no interaction, the 
reporter generates only DsRed-Express protein. Interaction produces both DsRed-Express 
and GFP. (B) Fluorescence microscopy of HEK293T cells transfected with plasmids 
encoding BMPR-II fused to the activation domain (BMPRII-AD) and TAK1 fused to the 
DNA binding domain (TAK1-DBD) compared to reporter alone (TN126). (C) Enzyme based 
reporter assay. DsRed-Express and GFP genes are replaced by genes encoding β-
galactosidase and luciferase (33). (D) Fold activation in HEK293T cells transfected with the 
enzyme-based reporter, BMPR-II-AD, or TAK1-DBD plasmids. (E) The efficiency of the 
interaction of BMPR-II with ALK3 and TAK1.  The efficiency of the interaction between 
BMPR-II and TAK1 was set as 1. (F) The relative luc-gal ratio in cells overexpressing mutant 
BMPR-II and TAK1 compared to the wild-type BMPR-II receptor. Data are presented as 
mean ± SD from 3–6 independent experiments. Pr- promoter, D/A unit- 
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deactivation/activation unit for downstream transcription (33). ***P<0.001 compared with 
reporter or reporter transfected with BMPR-II-AD and TAK1-DBD plasmids. AD indicates 
activation domain; DBD, DNA-binding domain. 
Figure 7 
Model depicting the regulation of TGFβ-induced SMAD-independent MAPK pathways in 
healthy individuals (A) and PAH subjects harbouring a mutation in the BMPR2 gene (B).  (A) 
BMPR-II–mediated signaling controls the SMAD1/5/8 pathway, and regulates proliferation 
and apoptosis. In the presence of fully functional BMPR-II–mediated signaling (heavier 
arrows), the MAPK-mediated anti-apoptotic and pro-proliferative activity of TGFβ signaling 
is restricted (thinner arrows).  The arrows from the central TAK1 pool denote the availability 
of TAK1 for both the BMP and TGFβ pathways. In BMP signaling, TAK1 is retained by the 
BMPR-II receptor complex. (B) BMPR-II dysfunction may alter the ratio of cell apoptosis to 
proliferation and thereby mediating pulmonary vascular hypertrophy. Mutation in BMPR2 
impairs SMAD1/5/8 signaling and makes TAK1 accessible to the TGFβ receptor complex, 
leading to abnormal proliferation and apoptosis (heavier arrows). Selected inhibition of the 
TGFβ-mediated TAK1-MAPK pathways by chemical agents is indicated. 
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Supplementary data 
 
Materials and Methods 
RNA isolation, cDNA synthesis and reverse Transcriptase PCR (RT-PCR) 
RNA was isolated from mammalian cells using TRI-Reagent (Sigma), cDNA was 
synthesized using random primers and MMLV Reverse Transcriptase (Promega) 
following manufacturer’s protocol. Total lung tissue RNA was extracted using the Trizol 
method (Invitrogen). 2 ug RNA was then reverse transcribed using Thermoscript RT-
PCR kits (Invitrogen). The PCR was carried out using Hi-Fidelity Extensor Master Mix 
(ABgene). Quantitative PCR for determining transcripts of BMPR2, PAI-1, TAK1, Id1 and 
β-2 microglobulin were performed using TaqMan Gene Expression Assay (Applied 
Biosystems) on 7900HT Fast Real-Time PCR system (Applied Biosystems) according to 
the manufacturer’s protocol. 
Generation of constructs for protein-protein interactions assay 
The coding sequence of full-length human TAK1 (accession number BC017715) lacking 
the first amino acid was cloned into BamHI and XbaI sites of pTN111 vector (1). The 
resulting plasmid contains a N-terminal DNA binding domain (DBD) adjacent to the 
human TAK1, the fidelity of which was verified by restriction analyses and sequencing. 
Efficiency of protein-protein interactions between TAK1 and BMPRII in mammalian cells 
was determined as previously reported 
(http://www.natureprotocols.com/2007/06/28/efficiency_of_proteinprotein_i_1.php). In 
brief the intracellular domain of BMPR-II was fused with VP-16 activation domain (2) 
whilst TAK1 was fused with a DBD. Plasmids encoding both fusion proteins were 
transfected into human embryonic kidney (HEK293) cells together with the gal-luc and 
DsRed-Express-GFP reporters (pTN114 and pTN126; (2)). In the event of an interaction 
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both reporter proteins will be generated with the ratio of reporter activities producing a 
measure of the efficiency of protein-protein interactions.  
Details of the other expression constructs used in this study are available upon request.    
Cell culture, transient transfection, enzymatic and fluorescence assay  
Cell culture and transfections were carried out as described elsewhere (2), (3). 
Luciferase and β-galactosidase activities were determined with the Dual-light Reporter 
Assay systems (Applied Biosystems) using an ORION-II Plate Luminometer (Berthold) 
according to manufacturers protocols. BMP-responsive reporter assay in mammalian 
cells was performed as previously described (2).  For determination of fluorescence 
intensity, cells were grown in 96 well black plate and 24 hours after transfection medium 
was replaced by DMEM containing 0.1%FBS and grown for an additional 48 hours. At 
the time of measurement, the medium was discarded and the fluorescence intensities 
were determined using BMG Labtech Omega fluorescence plate reader. 
Quantification of proliferation and apoptosis of mouse primary PASMCs 
To determine proliferation, cells were seeded at 0.2X10 5 per well in a clear 96 well plate 
in DMEM containing 10% FBS. Twenty four hours later, the medium was replaced by 
either fresh DMEM/0.1% FBS alone or containing TGFβ1 (10ng/ml) (R&D Systems), 
SD208 (10µM) (TOCRIS), SB203580 (0.1-10 µM) (TOCRIS), (5Z)-7-Oxozeaenol (0.1-10 
µM) (TOCRIS) and U0126 (0.1-10 µM) (TOCRIS)  and grown for additional for 4-5 days. 
The relative rate of cell proliferation was determined using CellTiter 96® Aqueous One 
Solution Cell Proliferation Assay (Promega) following manufacturer’s protocol. 
Absorbance was recorded at 490nm using Omega Plate Reader (BMG Labtech) at 1, 2 
and 3 hours intervals.  
For apoptosis assays, cells were seeded as mentioned before with the exceptions that a 
white 96 well plate was used and assays were carried out 24 hours after the treatment. 
For induction of apoptosis cells were treated with staurosporine for overnight at 
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concentrations of 0.2µM.  Apoptosis assays were carried out using Caspase-Glo® 3/7 
Assay (Promega) following manufacturer’s instruction. Luminescence was recorded 
using ORION-II Plate Luminometer (Berthold).  
Western blots analysis 
Mouse PASMCs grown in either 6 or 12 well plates were washed with PBS and lysed 
with 1X Reporter Lysis Buffer (Promega) containing protease and phosphatase inhibitor 
cocktail (Rochae) together with 1X SDS loading dye in a plate shaker at room 
temperature for 20 minutes. Cell extracts from HEK293 cells were prepared as above 
with the exception that cells were undergone a repeated freeze and thaw cycle and 
without the SDS dye. Cells were centrifuged at 14,000g at 4ºC for 15 minutes. Lung 
tissues were put (100-200mg) into the Lysing Matrix D tubes (MP Biomedicals), which 
contain 1ml phosphate buffer (100mM DO4 [K2HPO4:KH2PO4 = 3:1], 1mM EDTA, 1mM 
DTT) supplemented with protease inhibitor (Roche). Tissues were homogenated by 
Hybaid Ribolyser (Hybaid). The protein concentration of the homogenants is determined 
by BCA protein assay (Thermo scientific).The protein suspension was separated on a 
(4-20%) SDS-PAGE gel (Bio-Rad), transferred onto a nitrocellulose membrane 
(Whatmann) and incubated with blocking buffer (1X TBS, 0.1% Tween-20 with 5% w/v 
nonfat dry milk). Membranes were incubated with phospho-specific p38MAPK 
(Thr180/Thr182), TAK1 (Thr184/187), ERK1/2 (Thr202/Tyr204) and total TAK1 (Cell 
signaling) antibodies following manufacturer’s protocols. The membrane was developed 
with an enhanced chemiluminescence reagent (ECL Plus Western blotting Detection 
Reagents, Amersham). To confirm equal loading the membranes were stripped and re-
probed with anti-β-actin antibody (Cell Signaling).  
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Supplementary Figure Legends 
Supplementary Figure 1 
Effect of nonsense mutation in the bmpr2 gene on BMP signaling measured on Id1 gene 
expression. Determination of the bmpr2 (A) and Id1 (B) transcripts relative to β-2-
microglobulin (b2mg) in mouse primary PASMCs by quantitative PCR. (C) As in (A), in 
hypoxic rat lungs. ***P<0.001 compared with wild type PASMCs. 
Supplementary Figure 2 
The anti-apoptotic phenotype of bmpr2 mutant PASMCs was rescued by U0126 
treatment. Activation of caspase 3/7 activity in the absence (A) and presence of TGFβ 
stimulation (B). U0126 activates caspase activity in a dose dependent manner. The 
relative caspase activity of untreated mutant cells (0.1% FCS) was set as 100. *P<0.05, 
**P<0.01 and ***P<0.001 compared with untreated cells. 
Supplementary Figure 3 
Increased expression of TAK1 in hypoxic PAH rat lungs and PAH-PASMCs. (A) RT-PCR 
analysis of TAK1 transcripts in lung samples derived from normoxic and hypoxic rats 
(n=3).  (B) Quantification of RT-PCR by image analysis. (C) RT-PCR of TAK1 transcripts 
in PAH-PASMCs. The sizes of DNA bands derived from TAK1 and GAPDH transcripts 
are indicated.  
Supplementary Figure 4 
Activation of TAK1 in PAH rat lungs. (A) Western blot analysis of total TAK1 proteins in 
hypoxic rat lungs detecting a long (TAK1-LF) and a short (TAK1-SF) isoform. Transient 
activation of TAK1-SF in hypoxic PAH rat model (B-C). Data associated with time course 
2 days and 1 week were presented in Figure 4B-C and are included here for comparison.  
(D) TAK1-SF was phosphorylated following 1 week (see Figure 4D) but not in 2 and 4 
week of monocrotaline treatment. (E) Oxozeaenol treatment and BMP9 stimulation 
inhibit the phophorylation of TAK1-SF in HEK293T cells.  (F) Western blot using phopho-
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ERK1/2 antibody in a time course of hypoxic rat lungs. ***P<0.001 compared with 
normoxia. 
Supplementary Figure 5 
Negative regulation of TAK1 by BMP signaling in HEK293 cells. (A) BMP9 inhibits the 
phosphorylation of endogenousTAK1-SF and overexpressed TAK1.  (B) SMAD1 
overexpression inhibits the phosphorylation of TAK1 in a dose dependent manner.  (C) 
SMAD1 mediated inhibition of TAK1 phosphoryaltion was rescued by overexpression of 
TAK1. 
Supplementary Figure 6 
Inhibition of BMP signalling by TAK1. (A) Effect of TAK1 on BMP signaling measured on 
the 3GC2-Lux reporter in the presence of plasmids encoding BMPR-II, ALK3, ALK6, and 
TAK1 in HEK293 cells stimulated with BMP4 ligand. (B) Competition between TAK1 and 
SMAD1. Concentration of SMAD1 plasmid was 100ng whilst the TAK1 plasmid was 
transfected at 5, 10, 15 and 20ng as indicated. (C) Effect of BMPR-II overexpression on 
TAK1–mediated inhibition of reporter activity. Concentration of TAK1 plasmid was 
0.25ng whilst the BMPR-II plasmid was transfected at 1:1, 1:10 and 1:100 ratio as 
indicated. The presence and absence of TAK1, SMAD1 and BMPR-II plasmid were 
indicated by (+) and (-), respectively.  Data are presented as mean ± SD which were 
derived from 3 independent experiments. **P<0.01 and ***P<0.001 compared with 
reporter. 
Supplementary Figure 7 
Interaction of TAK1 and BMPR-II determined by  mammalian two hybrid dual-
fluorescence protein interactions assay (1).  (A) The relative GFP-DsRed-Express ratio 
in HEK293T cells overexpressing BMPR-II-AD and TAK1-DBD together with the 
fluorescence reporter (TN126).  The ratio was both fluorescence intensities was 
compared in cells transfected with reporter alone or with TAK-DBD.  (B) The efficiency of 
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interactions of BMPR-II with ALK3 and TAK1 determined by the fluorescence assay.  
Efficiency of interactions between BMPR-II and TAK1 was set as 1.  Data are presented 
as mean ± SD which were derived from 3 independent experiments. ***P<0.001 
compared with reporter. 
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